First FDA-Approved Implant Treatment for MacTel Eye Disease

Encelto (revakinagene taroretcel-lwey) is an allogeneic encapsulated cell-based gene therapy — a small opaque semi-permeable capsule (about grain-of-rice scale; width ~1.2 mm, length ~6.1 mm) containing living retinal pigment epithelial cells that continuously secrete rhCNTF, surgically placed into the vitreous. On the US Prescribing Information (Initial U.S. Approval 2025; DailyMed updated through 26 Aug 2026) it is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

This is a traditional FDA biologic approval (CBER). The FDA approved STN BLA 125798/0 on 5 March 2025. Product page lists Neurotech Pharmaceuticals, Inc. U.S. License number on the PI: 2321. Associated pivotal NCT numbers: NCT03316300 (Study 1 / Protocol A) and NCT03319849 (Study 2 / Protocol B).

Distinct path — not this label: Observation alone, nutritional supplements alone, or anti-VEGF injections for neovascular complications alone are not this encapsulated rhCNTF implant label. Pediatric MacTel is not an established labelled population. Neovascular MacTel was excluded from the pivotal enrollment criteria. Other retinal dystrophies without labelled MacTel indication are not this population. Today’s approved US encapsulated cell-implant treatment pathway for idiopathic MacTel is Neurotech Encelto STN 125798.

Manufactured by Neurotech Pharmaceuticals, Inc., Building 1, Suite 101, Cumberland, RI 02864. Commercial access is organised through vitreoretinal surgeons and ENCELTOconnect patient-access support.

Where this is taking place

Approved prescription route today: United States — FDA-labelled Encelto for adults with idiopathic MacTel, administered only after ophthalmology assessment (including SD-OCT ellipsoid-zone imaging in the pivotal logic), enrollment coordination, and outpatient vitreoretinal surgery under aseptic conditions by a qualified ophthalmologist. Product / AE contact on PI: Neurotech 1-833-963-9275. Patient access consultants: ENCELTOconnect 1-877-ENCELTO (1-877-362-3586), Mon–Fri 8 AM–8 PM ET. This is a centre-administered surgical implant conversation — not a retail pharmacy pickup and not a DIY import.

Company and partner materials describe US implantation through qualified vitreoretinal surgeons at authorized facilities. Examples in public press have included centres such as Stanford Byers Eye Institute and various regional retina practices. Treat named-centre lists as dynamic. Ask ENCELTOconnect / the treating retina clinician for the current referral path. Do not assume every eye hospital already implants Encelto.

Outside the United States: At the time of writing, no confirmed Health Canada Notice of Compliance / DIN for Encelto. Do not import on your own. Historical research geography is not the same sentence as a Canadian or other foreign marketing authorisation for your home regulator.

NTMT-03-A — NCT03316300 (ClinicalTrials.gov: completed) and NTMT-03-B — NCT03319849 (completed) — Twin multicenter, randomized, sham-controlled Phase 3 studies. Phase 4 long-term follow-up NCT06971939 is listed recruiting on ClinicalTrials.gov (retrieved 21 Sep 2026) — that is a follow-up / extension research path, not the approved implant prescription route. Labelled commercial access is through vitreoretinal centres and ENCELTOconnect. Completed pivotal enrolment is not walk-in research recruitment.

The practical prescription route in the US is a retina / vitreoretinal team working with ENCELTOconnect to confirm idiopathic MacTel, map surgical candidacy, arrange payer / travel logistics, and schedule implant (and possible later removal if clinically required).

Approval matrix

Access by country

• United States: Ask a retina / vitreoretinal clinician about referral for FDA-labelled Encelto. Labelled 5 March 2025. Path: confirm idiopathic MacTel → surgical candidacy (no active ocular/periocular infection; no known Endo-SFM hypersensitivity) → ENCELTOconnect enrollment 1-877-362-3586 → outpatient implant of one device per affected eye → postoperative antibiotic and steroid taper → ongoing positioning checks. AE / implant return: Neurotech 1-833-963-9275. No list price or copay dollars in this article. This is US labelled supply through surgical centres, not a DIY import.

• Canada: Encelto authorisation not confirmed. Ask the Canadian retina clinic what legal paths exist in Canada when a Canadian Encelto label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Confirm your local regulator’s current status with the treating centre. A US implant lot is not a foreign pack. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting.

Who is eligible (from the US label)

This is a surgical encapsulated cell-implant conversation on the Prescribing Information — not a walk-in eye drop, and not established in pediatrics.

United States (USPI):

• Indication: Treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).
• Dose: One ENCELTO implant per affected eye containing 200,000–440,000 allogeneic RPE cells expressing rhCNTF; surgical intravitreal placement only.
• Contraindications: Active or suspected ocular or periocular infections; known hypersensitivity to Endothelial Serum Free Media (Endo-SFM).
• Warnings: Severe vision loss (≥15 ETDRS letters); infectious endophthalmitis; retinal tear and/or detachment; vitreous hemorrhage (interrupt antithrombotic medicines before surgery when appropriate); implant extrusion; cataract formation/progression; suture-related complications; delayed dark adaptation (caution driving / dark navigation).
• Most common adverse reactions (≥2% and higher than sham, pooled): conjunctival hemorrhage (31%), delayed dark adaptation (23.1%), foreign body sensation (15%), eye pain (15%), suture-related complications (15.4%), miosis (15.4%), and others listed in USPI Table 1; serious reactions included suture complications and implant extrusion.
• Pediatrics: Safety/effectiveness not established.
• Geriatrics: 38/117 (32%) were ≥65 in the pooled safety set; numbers were not sufficient to determine differential response.
• MR Conditional: Patients receive an implant card for MRI technicians.

Not labelled on the sources checked for this article:

• Pediatric MacTel.
• Neovascular MacTel as a pivotal-included population.
• Canadian (and several other) marketing authorisations (not confirmed here).
• Treating completed pivotal enrolment as open commercial trial recruitment.
• Application outside a qualified vitreoretinal surgical path.

How to access (United States)

1. See a retina specialist experienced with MacTel imaging (SD-OCT ellipsoid zone) and vitreoretinal surgery.
2. Confirm idiopathic MacTel and discuss whether an Encelto implant is appropriate for each eye.
3. Call or have the clinic enroll with ENCELTOconnect (1-877-362-3586) for benefits verification and delivery coordination.
4. Plan perioperative steps: possible pause of antithrombotic medicines, outpatient surgery, 1-week activity/water restrictions, antibiotic drops, steroid taper, eye shield, and follow-up exams (including positioning checks).
5. Keep the implant card for any future MRI.
6. Authorised is not funded — insurance and assistance paths vary; no prices in this article.

Evidence snapshot (labelled pivotal)

Study 1 — NTMT-03-A / NCT03316300 (completed):

• Adults with MacTel; EZ break 0.16–2.00 mm²; BCVA ≥54 ETDRS letters (~20/80 or better); neovascular MacTel excluded.
• Efficacy population 115 (Encelto 58 / sham 57); mean age 61.
• Primary: rate of EZ area loss over 24 months — Encelto 0.075 vs sham 0.166 mm² (difference −0.091; p <0.0001).
• Secondary microperimetry aggregate sensitivity loss: difference −17.75 dB (p 0.02).

Study 2 — NTMT-03-B / NCT03319849 (completed):

• Same broad MacTel criteria; efficacy population 113 (Encelto 59 / sham 54); mean age 59.
• Primary EZ loss rate: Encelto 0.111 vs sham 0.160 mm² (difference −0.049; p 0.0186).
• Secondary microperimetry difference −1.95 dB (p 0.83) — primary met; this secondary did not.

Phase 4 — NCT06971939 (recruiting): Long-term safety/efficacy follow-up including prior sham participants — research status, not the commercial route.

How to talk with a doctor

Bring this page and ask a retina / vitreoretinal clinician:

1. “I have idiopathic MacTel. Is labelled US Encelto a fit for one or both eyes, and which centre would implant it?”
2. “What is the current ENCELTOconnect intake step (1-877-362-3586), and how do benefits and scheduling work?”
3. “What are the surgical risks (vision loss, infection, retinal tear, extrusion), and what is the postoperative drop / activity plan?”
4. “How will delayed dark adaptation affect driving, and when do we recheck implant position?”
5. If outside the US: “Has our regulator authorised Encelto, or what legal special-access options exist?”

Who is involved (from primary sources)

• License holder / manufacturer: Neurotech Pharmaceuticals, Inc., Cumberland, RI 02864 — U.S. License 2321 (USPI).
• Patient support: ENCELTOconnect — 1-877-362-3586 (encelto.com patient-support).
• Pivotal / related programs: NCT03316300, NCT03319849; Phase 4 NCT06971939.
• Product / AE / implant return contact on USPI: Neurotech 1-833-963-9275.

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted.

Sources

• FDA CBER product page — ENCELTO (STN BLA 125798)
• FDA Summary Basis for Regulatory Action / Approval Letter — 5 Mar 2025
• DailyMed / FDA Package Insert — ENCELTO (NDC 82958-501-01; License 2321)
• ClinicalTrials.gov NCT03316300 (completed), NCT03319849 (completed), NCT06971939 (recruiting)
• ENCELTOconnect patient-support materials (1-877-362-3586; AE 1-833-963-9275)

Authorized is not funded. Not medical advice.